Voyager Therapeutics, Inc.
DIRECTED EVOLUTION
Last updated:
Abstract:
The disclosure provides compositions and methods for the preparation, manufacture, formulation and therapeutic use of adeno-associated virus (AAV) particles for the prevention and/or treatment of diseases.
Status:
Application
Type:
Utility
Filling date:
16 May 2019
Issue date:
15 Jul 2021